Icardio.AI

iCardio.ai, founded in 2019, is a Los Angeles-based company specializing in the development of deep learning algorithms for ultrasound imaging, particularly focused on echocardiography. The company's core product, the Ultrasound Cardiography Brain platform, utilizes over 60 machine learning algorithms to enhance the accuracy of cardiovascular diagnoses. This platform is capable of performing various tasks such as automatically classifying cardiac views, identifying crucial linear measurements of the heart, and evaluating cardiomyopathies and heart valve abnormalities like aortic stenosis. iCardio.ai's technology is trained on a proprietary dataset of over 200 million ultrasound images, positioning it as one of the largest-scale radiological AI products globally. The company's software aims to automate critical heart measurements, detect valvular diseases, and provide image quality assessments. In February 2024, iCardio.ai received Breakthrough Device designation from the FDA for its Aortic Stenosis screening tool, which can predict aortic stenosis from a single ultrasound clip, enabling precise screening in diverse settings such as primary care or outpatient clinics.

Key customers and partnerships

iCardio.ai has established partnerships with several prominent organizations in the healthcare technology sector. In November 2023, the company joined Butterfly Garden, an AI Marketplace by Butterfly Network, with the goal of integrating its cardiac ultrasound AI tools with Butterfly's single-probe, whole-body handheld ultrasound system. This collaboration aims to make iCardio.ai's tools accessible to Butterfly's user base of over 100,000 providers. In April 2024, iCardio.ai partnered with Viz.ai to advance the rapid detection of aortic stenosis and facilitate patient triage by incorporating iCardio.ai's ultrasound interpretation technology into Viz.ai's comprehensive care coordination solution. Additionally, iCardio.ai has teamed up with some of the largest ultrasound vendors to deliver its technology to clinicians globally.